Association of PD-L1 expression with driver gene mutations and clinicopathological characteristics in non-small cell lung cancer : A real-world study of 10 441 patients
© 2024 The Authors. Thoracic Cancer published by John Wiley & Sons Australia, Ltd..
BACKGROUND: Programmed death ligand-1 (PD-L1) expression is a well-known predictive biomarker of response to immune checkpoint blockade in non-small cell lung cancer (NSCLC). However, there is limited evidence of the relationship between PD-L1 expression, clinicopathological features, and their association with major driver mutations in NSCLC patients in Latin America.
METHODS: This retrospective study included patients from Argentina with advanced NSCLC, and centralized evaluation of PD-L1 expression concurrently with genomic alterations in the driver genes EGFR, ALK, ROS1, BRAF, and/or KRAS G12C in FFPE tissue samples.
RESULTS: A total of 10 441 patients with advanced NSCLC were analyzed. Adenocarcinoma was the most frequent histological subtype (71.1%). PD-L1 expression was categorized as PD-L1 negative (45.1%), PD-L1 positive low-expression 1%-49% (32.3%), and PD-L1 positive high-expression ≥50% (22.6%). Notably, current smokers and males were more likely to have tumors with PD-L1 tumor proportion score (TPS) ≥50% and ≥ 80% expression, respectively (p < 0.001 and p = 0.013). Tumors with non-adenocarcinoma histology had a significantly higher median PD-L1 expression (p < 0.001). Additionally, PD-L1 in distant nodes was more likely ≥50% (OR 1.60 [95% CI: 1.14-2.25, p < 0.01]). In the multivariate analysis, EGFR-positive tumors were more commonly associated with PD-L1 low expression (OR 0.62 [95% CI: 0.51-0.75], p < 0.01), while ALK-positive tumors had a significant risk of being PD-L1 positive (OR 1.81 [95% CI: 1.30-2.52], p < 0.01).
CONCLUSIONS: PD-L1 expression was associated with well-defined clinicopathological and genomic features. These findings provide a comprehensive view of the expression of PD-L1 in patients with advanced NSCLC in a large Latin American cohort.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Thoracic cancer - 15(2024), 11 vom: 15. Apr., Seite 895-905 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ruiz, Gonzalo [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 16.04.2024 Date Revised 25.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/1759-7714.15244 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369459938 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369459938 | ||
| 003 | DE-627 | ||
| 005 | 20240425233058.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240308s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/1759-7714.15244 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM369459938 | ||
| 035 | |a (NLM)38456253 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ruiz, Gonzalo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Association of PD-L1 expression with driver gene mutations and clinicopathological characteristics in non-small cell lung cancer |b A real-world study of 10 441 patients |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.04.2024 | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 The Authors. Thoracic Cancer published by John Wiley & Sons Australia, Ltd. | ||
| 520 | |a BACKGROUND: Programmed death ligand-1 (PD-L1) expression is a well-known predictive biomarker of response to immune checkpoint blockade in non-small cell lung cancer (NSCLC). However, there is limited evidence of the relationship between PD-L1 expression, clinicopathological features, and their association with major driver mutations in NSCLC patients in Latin America | ||
| 520 | |a METHODS: This retrospective study included patients from Argentina with advanced NSCLC, and centralized evaluation of PD-L1 expression concurrently with genomic alterations in the driver genes EGFR, ALK, ROS1, BRAF, and/or KRAS G12C in FFPE tissue samples | ||
| 520 | |a RESULTS: A total of 10 441 patients with advanced NSCLC were analyzed. Adenocarcinoma was the most frequent histological subtype (71.1%). PD-L1 expression was categorized as PD-L1 negative (45.1%), PD-L1 positive low-expression 1%-49% (32.3%), and PD-L1 positive high-expression ≥50% (22.6%). Notably, current smokers and males were more likely to have tumors with PD-L1 tumor proportion score (TPS) ≥50% and ≥ 80% expression, respectively (p < 0.001 and p = 0.013). Tumors with non-adenocarcinoma histology had a significantly higher median PD-L1 expression (p < 0.001). Additionally, PD-L1 in distant nodes was more likely ≥50% (OR 1.60 [95% CI: 1.14-2.25, p < 0.01]). In the multivariate analysis, EGFR-positive tumors were more commonly associated with PD-L1 low expression (OR 0.62 [95% CI: 0.51-0.75], p < 0.01), while ALK-positive tumors had a significant risk of being PD-L1 positive (OR 1.81 [95% CI: 1.30-2.52], p < 0.01) | ||
| 520 | |a CONCLUSIONS: PD-L1 expression was associated with well-defined clinicopathological and genomic features. These findings provide a comprehensive view of the expression of PD-L1 in patients with advanced NSCLC in a large Latin American cohort | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a driver mutations | |
| 650 | 4 | |a genomic alterations | |
| 650 | 4 | |a immunohistochemistry (IHC) | |
| 650 | 4 | |a non‐small cell lung cancer (NSCLC) | |
| 650 | 4 | |a programmed death‐ligand 1 (PD‐L1) | |
| 650 | 7 | |a Protein-Tyrosine Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a B7-H1 Antigen |2 NLM | |
| 650 | 7 | |a Anaplastic Lymphoma Kinase |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins |2 NLM | |
| 650 | 7 | |a ErbB Receptors |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Enrico, Diego |e verfasserin |4 aut | |
| 700 | 1 | |a Mahmoud, Yamil D |e verfasserin |4 aut | |
| 700 | 1 | |a Ruiz, Alan |e verfasserin |4 aut | |
| 700 | 1 | |a Cantarella, María Florencia |e verfasserin |4 aut | |
| 700 | 1 | |a Leguina, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Barberis, Mariana |e verfasserin |4 aut | |
| 700 | 1 | |a Beña, Asunción |e verfasserin |4 aut | |
| 700 | 1 | |a Brest, Esteban |e verfasserin |4 aut | |
| 700 | 1 | |a Starapoli, Solange |e verfasserin |4 aut | |
| 700 | 1 | |a Mendoza Bertelli, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Tsou, Florencia |e verfasserin |4 aut | |
| 700 | 1 | |a Pupareli, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Coppola, María Pía |e verfasserin |4 aut | |
| 700 | 1 | |a Scocimarro, Alejandra |e verfasserin |4 aut | |
| 700 | 1 | |a Sena, Susana |e verfasserin |4 aut | |
| 700 | 1 | |a Levit, Patricio |e verfasserin |4 aut | |
| 700 | 1 | |a Perfetti, Aldo |e verfasserin |4 aut | |
| 700 | 1 | |a Aman, Enrique |e verfasserin |4 aut | |
| 700 | 1 | |a Girotti, María Romina |e verfasserin |4 aut | |
| 700 | 1 | |a Arrieta, Oscar |e verfasserin |4 aut | |
| 700 | 1 | |a Martín, Claudio |e verfasserin |4 aut | |
| 700 | 1 | |a Salanova, Rubén |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Thoracic cancer |d 2010 |g 15(2024), 11 vom: 15. Apr., Seite 895-905 |w (DE-627)NLM251832414 |x 1759-7714 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2024 |g number:11 |g day:15 |g month:04 |g pages:895-905 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/1759-7714.15244 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2024 |e 11 |b 15 |c 04 |h 895-905 | ||